8-K: Seres Therapeutics to Sell VOWST Business to Nestl Health Science for Up to $525 Million

Seres Therapeutics has agreed to sell its VOWST business to Nestl Health Science for a total potential consideration of up to $525 million, including upfront payments, milestone payments, and an equity investment.

Summary

• Seres Therapeutics has entered into an agreement to sell its VOWST business to Nestl Health Science.
• The deal includes an upfront payment of $100 million, less approximately $20 million for net obligations, a $60 million prepayment of a future milestone, and a $15 million equity investment in Seres common stock.
• Seres is also due to receive $75 million in installment payments in 2025, contingent on meeting transition obligations.
• There is a potential for up to $275 million in additional milestone payments based on VOWST net sales targets.
• The transaction is expected to close within the next 90 days, subject to shareholder approval and other customary conditions.
• Seres will provide transition services through the first quarter of 2025 and manufacturing support through the end of 2025.
• Seres will share 50/50 in the profit and loss of the VOWST business through the end of 2025.
• The company plans to use the proceeds to retire its debt and advance its pipeline, particularly SER-155.
• Seres expects to reduce its workforce by more than one-third following the closing of the deal.
• The company anticipates its cash runway will extend into Q4 2025 based on the deal economics and operating plans.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the significant cash infusion, debt retirement, and extended cash runway. However, there are some concerns about the loss of the VOWST business and the workforce reduction, which temper the overall positive outlook.

Positives

• The sale of the VOWST business provides a significant cash infusion of up to $525 million.
• The deal allows Seres to retire its debt obligations.
• The transaction extends Seres' cash runway into Q4 2025.
• Seres can now focus on its pipeline, particularly SER-155, and other cultivated live biotherapeutics.
• The company will streamline operations and reduce cash burn by reducing its workforce.
• The deal includes a 10% premium on the equity investment based on the 30-day volume weighted average price prior to the announcement of the Memorandum of Understanding.

Negatives

• Seres will lose full control of the VOWST business, which was its first FDA-approved product.
• The company will reduce its workforce by more than one-third.
• The deal is subject to shareholder approval and other customary conditions, which could delay or prevent the transaction.
• The company will share 50/50 in the profit and loss of the VOWST business through the end of 2025, which could impact reported results and liquidity.
• There is uncertainty regarding the timing and amount of future milestone payments.

Risks

• The transaction may not close if shareholder approval is not obtained or other conditions are not met.
• There is a risk of disruption to Seres' business operations during the transition period.
• The company may not receive all of the potential milestone payments.
• The 50/50 profit and loss sharing arrangement could negatively impact Seres' financial results.
• The company's ability to successfully develop and commercialize its pipeline products is not guaranteed.
• There is a risk that the company may not be able to retain key personnel after the transaction.

Future Outlook

Seres will focus on developing next-generation live biotherapeutic candidates, particularly SER-155, for medically vulnerable populations, leveraging the clinical and regulatory success of VOWST. The company anticipates its cash runway will extend into Q4 2025.

Management Comments

• Eric Shaff, President and Chief Executive Officer of Seres, stated that the transaction provides meaningful capital to support Seres pipeline advancement.
• Mr. Shaff also mentioned that they are proud of their accomplishments in bringing VOWST to the market and look forward to applying their approach to transform care in new patient groups.
• Mr. Shaff noted that the capital from the transaction will be used to strengthen the balance sheet, retire debt, and advance the pipeline.

Industry Context

This transaction reflects a trend of larger pharmaceutical companies acquiring promising assets from smaller biotech firms. Nestl Health Science, having previously partnered with Seres on VOWST, is now taking full ownership, indicating a strong belief in the product's potential. This deal also highlights the growing interest in microbiome-based therapeutics.

Comparison to Industry Standards

• The deal structure, with a mix of upfront payments, milestone payments, and equity investment, is common in the biotech industry.
• The potential total consideration of up to $525 million is significant for a company of Seres' size, suggesting a high valuation for the VOWST business.
• Comparable deals in the microbiome space include the acquisition of Rebiotix by Ferring Pharmaceuticals, which also involved an upfront payment and potential milestone payments.
• The focus on pipeline development after the sale is a common strategy for biotech companies that have divested assets.

Stakeholder Impact

• Shareholders will benefit from the cash infusion and potential for future growth.
• Employees will be impacted by the workforce reduction, with some transitioning to Nestl.
• Customers will see a change in ownership of the VOWST product.
• Suppliers will need to adjust to the new ownership of the VOWST business.
• Creditors will benefit from the retirement of Seres' debt.

Next Steps

• Seres will seek shareholder approval for the transaction.
• The transaction is expected to close within the next 90 days.
• Seres will provide transition services to Nestl through the first quarter of 2025.
• Seres will continue to advance its pipeline, particularly SER-155.
• Seres will reduce its workforce by more than one-third after the deal closes.

Key Dates

Keywords

Seres Therapeutics, Nestl Health Science, VOWST, Asset Purchase Agreement, Live Biotherapeutics, Microbiome, SER-155, Milestone Payments, Debt Retirement, Cash Runway